Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

Menu

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
My View
Tags:
BioPharmaceutical

Nastech Finalizes Plans For RNAi Subsidiary To Focus On Phase II Inhaled Drug Programs

This article was originally published in The Pink Sheet Daily

  • News

Executive Summary

Restructuring includes spinning out RNAi business, reducing 30 percent of work force to conserve cash.

You may also be interested in...



Nastech Makes Further Job Cuts In Second-Round Restructuring

Eliminations will reduce cash burn to focus on near-term business initiatives like finding a new partner for teriparatide nasal spray.

Nastech Makes Further Job Cuts In Second-Round Restructuring

Eliminations will reduce cash burn to focus on near-term business initiatives like finding a new partner for teriparatide nasal spray.

Nastech Plans Phase II For Teriparatide Nasal Spray In Q1 2008 After P&G Returns Rights

Procter & Gamble notified the company of its decision to terminate a development deal for the teriparatide nasal spray for osteoporosis.

Table

View full table

Topics

Tags:
BioPharmaceutical
Latest Headlines

‘Unbalanced’ EU HTA Timelines Exacerbated By Rare Disease & Cancer Drugs

National Drug Stockpiles Create ‘False Sense Of Security’

Patent Office Issues Proposed Rule For Rarely Successful Director Review Requests

Medicare Spending Forecast For Leqembi Reflects CMS Angst About Alzheimer’s Drug Costs

See All
UsernamePublicRestriction

Register

PS065357

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By